Why Ascletis Pharma (SEHK:1672) Is Up 6.3% After FDA Clears ASC30 Diabetes Trial And Obesity Data

Simply Wall St.01-16

Ascletis Pharma Inc. reported that it has received U.S. FDA IND clearance for a 13‑week Phase II trial of its oral small‑molecule GLP‑1 candidate ASC30 in type 2 diabetes, following dosing plans up to...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2604403918?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-01-16 20:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2604403918","market":"sg","top_or_hot":-1,"title":"Why Ascletis Pharma (SEHK:1672) Is Up 6.3% After FDA Clears ASC30 Diabetes Trial And Obesity Data","media":"Simply Wall St.","content":"<div>\n<p>Ascletis Pharma Inc. reported that it has received U.S. FDA IND clearance for a 13‑week Phase II trial of its oral small‑molecule GLP‑1 candidate ASC30 in type 2 diabetes, following dosing plans up to...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1672/ascletis-pharma-shares/news/why-ascletis-pharma-sehk1672-is-up-63-after-fda-clears-asc30\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Ascletis Pharma (SEHK:1672) Is Up 6.3% After FDA Clears ASC30 Diabetes Trial And Obesity Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Ascletis Pharma (SEHK:1672) Is Up 6.3% After FDA Clears ASC30 Diabetes Trial And Obesity Data\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-16 20:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1672/ascletis-pharma-shares/news/why-ascletis-pharma-sehk1672-is-up-63-after-fda-clears-asc30><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ascletis Pharma Inc. reported that it has received U.S. FDA IND clearance for a 13‑week Phase II trial of its oral small‑molecule GLP‑1 candidate ASC30 in type 2 diabetes, following dosing plans up to...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1672/ascletis-pharma-shares/news/why-ascletis-pharma-sehk1672-is-up-63-after-fda-clears-asc30\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1672/ascletis-pharma-shares/news/why-ascletis-pharma-sehk1672-is-up-63-after-fda-clears-asc30","article_id":"2604403918","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1672/ascletis-pharma-shares/news/why-ascletis-pharma-sehk1672-is-up-63-after-fda-clears-asc30","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2604403918","pubTimestamp":1768566548,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Ascletis Pharma Inc. reported that it has received U.S. FDA IND clearance for a 13‑week Phase II trial of its oral small‑molecule GLP‑1 candidate ASC30 in type 2 diabetes, following dosing plans up to 80 mg and focusing on HbA1c, fasting glucose, weight, and safety outcomes.\nThe company also released Phase II obesity data showing dose‑dependent weight loss and relatively low discontinuation and vomiting rates, underlining ASC30’s potential as an in‑house oral GLP‑1 receptor agonist targeting...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","BK1515":"抗疫概念","BK1574":"生物医药B类股","01672":"歌礼制药-B"},"translate_title":"FDA批准ASC30糖尿病试验和肥胖数据后歌礼制药(SEHK：1672)为何上涨6.3%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01672":1.5},"content_text":"Ascletis Pharma Inc. reported that it has received U.S. FDA IND clearance for a 13‑week Phase II trial of its oral small‑molecule GLP‑1 candidate ASC30 in type 2 diabetes, following dosing plans up to 80 mg and focusing on HbA1c, fasting glucose, weight, and safety outcomes. The company also released Phase II obesity data showing dose‑dependent weight loss and relatively low discontinuation and vomiting rates, underlining ASC30’s potential as an in‑house oral GLP‑1 receptor agonist targeting both obesity and diabetes. We’ll now examine how the FDA’s IND clearance for ASC30 in diabetes could influence Ascletis Pharma’s broader investment narrative and outlook. Uncover the next big thing with financially sound penny stocks that balance risk and reward.AdvertisementWhat Is Ascletis Pharma's Investment Narrative?To own Ascletis Pharma, you really have to believe in its GLP‑1 platform turning a largely revenue‑light, loss‑making story into something more substantial. The FDA’s IND clearance for ASC30 in type 2 diabetes adds real substance to that belief: it takes the asset beyond obesity data and into a second, globally important indication, which strengthens the case for partnerships or future monetization. In the near term, key catalysts now cluster around ASC30’s diabetes Phase II readouts and China’s review of ASC40 for acne, while the biggest risks remain execution and funding for a broad, capital‑intensive pipeline at a company that is still unprofitable and volatile. Given the already very large 1‑year share price move, this new trial looks more like a validation of the story than a step‑change in the risk profile. However, there is one funding and dilution risk here that investors really should not ignore.\n\nOur expertly prepared valuation report on Ascletis Pharma implies its share price may be too high.Exploring Other PerspectivesSEHK:1672 1-Year Stock Price Chart The single fair value estimate from the Simply Wall St Community sits far from the current share price, underscoring how differently retail investors can view Ascletis. Set that against the heavy pipeline spend and ongoing losses discussed above, and it becomes clear why you might want to compare several viewpoints before forming your own expectations for the company’s next phase.Explore another fair value estimate on Ascletis Pharma - why the stock might be worth as much as HK$0.022!Build Your Own Ascletis Pharma NarrativeDisagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.A great starting point for your Ascletis Pharma research is our analysis highlighting 1 key reward and 4 important warning signs that could impact your investment decision.Our free Ascletis Pharma research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Ascletis Pharma's overall financial health at a glance.Contemplating Other Strategies?Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 24 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.Find companies with promising cash flow potential yet trading below their fair value.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2604403918","isCrawlerRequest":true}